×
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
S&P 500   4,158.24 (+2.47%)
DOW   33,212.96 (+1.76%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NYSE:NVTA

Invitae (NVTA) Stock Forecast, Price & News

$4.02
+0.52 (+14.86%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$3.55
$4.05
50-Day Range
$3.40
$9.01
52-Week Range
$3.32
$35.51
Volume
11.43 million shs
Average Volume
6.86 million shs
Market Capitalization
$921.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.89
30 days | 90 days | 365 days | Advanced Chart
Receive NVTA News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

Invitae logo

About Invitae

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$12.40 per share

Profitability

Net Income
$-379.01 million
Net Margins
-148.62%
Pretax Margin
-107.46%

Debt

Price-To-Earnings

Miscellaneous

Free Float
224,933,000
Market Cap
$921.74 million
Optionable
Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/27/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.28 out of 5 stars

Medical Sector

293rd out of 1,424 stocks

Medical Laboratories Industry

9th out of 33 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Invitae (NYSE:NVTA) Frequently Asked Questions

Is Invitae a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae
or view top-rated stocks.

When is Invitae's next earnings date?

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Invitae
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its quarterly earnings data on Tuesday, May, 3rd. The medical research company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.02. The medical research company earned $123.70 million during the quarter, compared to analyst estimates of $129.31 million. Invitae had a negative net margin of 148.62% and a negative trailing twelve-month return on equity of 24.48%. Invitae's quarterly revenue was up 19.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.63) earnings per share.
View Invitae's earnings history
.

What guidance has Invitae issued on next quarter's earnings?

Invitae updated its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $133.76 million-$139.57 million, compared to the consensus revenue estimate of $128.13 million.

What price target have analysts set for NVTA?

6 brokerages have issued twelve-month price targets for Invitae's stock. Their forecasts range from $8.50 to $35.00. On average, they anticipate Invitae's stock price to reach $20.25 in the next twelve months. This suggests a possible upside of 402.5% from the stock's current price.
View analysts' price targets for Invitae
or view top-rated stocks among Wall Street analysts.

Who are Invitae's key executives?
Invitae's management team includes the following people:
  • Dr. Sean Emerson George Ph.D., Co-Founder, Pres, CEO & Director (Age 48, Pay $500.15k)
  • Ms. Yafei Wen, Chief Financial Officer (Age 49, Pay $422.73k)
  • Mr. Kenneth D. Knight, Chief Operating Officer (Age 61, Pay $1M)
  • Mr. Thomas R. Brida, Gen. Counsel, Chief Compliance Officer & Sec. (Age 51, Pay $425k)
  • Dr. Robert L. Nussbaum, Chief Medical Officer (Age 72, Pay $391.35k) (LinkedIn Profile)
  • Ms. Shelly D. Guyer, Chief Sustainability Officer (Age 62, Pay $430.44k) (LinkedIn Profile)
  • Mr. Robert F. Werner, Chief Accounting Officer & Principal Accounting Officer (Age 49)
  • Mr. Karthik Suri, Chief Product & Technology Officer
  • Mr. Jackson J. Finks C.F.A., CFA, Director of Investor Relations & Strategic Fin.
  • Mr. Lee Bendekgey, Chief Policy Officer (Age 64)
What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (12.23%), Vanguard Group Inc. (8.51%), Sumitomo Mitsui Trust Holdings Inc. (8.21%), Nikko Asset Management Americas Inc. (8.21%), Canada Pension Plan Investment Board (1.66%) and Gilder Gagnon Howe & Co. LLC (1.49%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends for Invitae
.

Which major investors are selling Invitae stock?

NVTA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Goldman Sachs Group Inc., Zurcher Kantonalbank Zurich Cantonalbank , Gilder Gagnon Howe & Co. LLC, Group One Trading L.P., Wolverine Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., and Nikko Asset Management Americas Inc.. Company insiders that have sold Invitae company stock in the last year include Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, Thomas Brida, and Yafei Wen.
View insider buying and selling activity for Invitae
or view top insider-selling stocks.

Which major investors are buying Invitae stock?

NVTA stock was acquired by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Renaissance Technologies LLC, ARK Investment Management LLC, Rock Springs Capital Management LP, Bank of Montreal Can, Ergoteles LLC, Qube Research & Technologies Ltd, and American Century Companies Inc..
View insider buying and selling activity for Invitae
or or view top insider-buying stocks.

How do I buy shares of Invitae?

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $4.03.

How much money does Invitae make?

Invitae has a market capitalization of $924.03 million and generates $460.45 million in revenue each year. The medical research company earns $-379.01 million in net income (profit) each year or ($3.25) on an earnings per share basis.

How many employees does Invitae have?

Invitae employs 3,000 workers across the globe.

What is Invitae's official website?

The official website for Invitae is www.invitae.com.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at (415) 374-7782 or via email at [email protected].

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.